Literature DB >> 7260903

Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment.

V Tomazic, M J Ehrke, E Mihich.   

Abstract

In C57BL/6J mice, depending on the dose of P815 cells used for immunization, Adriamycin exerted different effects on the cell-mediated lytic response and complement-dependent cytotoxicity. At the dose of 3 X 10(7) P815 cells, Adriamycin treatment had no apparent effect on cell-mediated lytic response regardless of timing of drug treatment. At lower doses of antigen (10(7) or 5 X 10(6) cells), the response was augmented in Adriamycin-pretreated mice. Similarly, under conditions which led to a suboptimal complement-dependent humoral response of untreated control, Adriamycin pretreatment resulted in an augmented response; under conditions of maximal response, Adriamycin was suppressive. Suppression was maximal if the drug was injected at either the same time or shortly before or after antigen. The cell-mediated lytic response was proportional to the dose of antigen used, while the complement-dependent humoral lytic response was inversely proportional to dose of antigen in the range used in these experiments. Secondary cell-mediated lytic response in culture was also augmented if mice had been pretreated with Adriamycin 5 days before the primary immunization. The cell-mediated lytic response of spleen and peritoneal exudate cells from mice immunized with relatively low doses of P815 cells 5 days after treatment with Adriamycin was increased 12 to 15 days after immunization. The cytotoxic effects were present in both plastic adherent and nonadherent fractions of either spleen or peritoneal cell populations. All these effector cells were found to be anti-Thy 1.2 sensitive. The phagocytic activity of spleen cells was increased after immunization, but no drug effect was observed; following 24 hr of culture, however, cells from drug-treated immunized donors had increased phagocytic activity as compared to that of controls. Increased phagocytosis also developed in cells nonadherent to plastic.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7260903

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.

Authors:  D L Maccubbin; S A Cohen; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.

Authors:  S Nanbara; S Arinaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C.

Authors:  T Akiyoshi; S Arinaga; H Tsuji
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.

Authors:  G Hisano; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Effects of low-dose mafosfamid on the lymphokine-activated killer cell activity of peripheral blood mononuclear cells determined by a clonogenic microassay.

Authors:  H R Maurer; C Echarti
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

6.  A trial of postoperative adjuvant combination chemo-immunotherapy for stage IV gastric carcinoma.

Authors:  T Akiyoshi; S Arinaga; K Takamuku; T Wada; F Koba; H Tsuji
Journal:  Jpn J Surg       Date:  1988-09

7.  Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Authors:  Yesim Eralp; Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; John M Polo; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2004-04-07       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.